Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    Patient safety
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    September 28, 2022
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    Radiation therapy
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    August 19, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Prostate cancer

    Hispanic Patients Are at Higher Risk for Aggressive Prostate Cancer but Less Likely to Get Treatment
    Special Populations

    Hispanic Patients Are at Higher Risk for Aggressive Prostate Cancer but Less Likely to Get Treatment

    Compared to their non-Hispanic White counterparts, most Hispanic patients with localized prostate cancer are nearly 20% more likely to have aggressive disease, but the risk varies based on their country of origin, researchers reported in study findings published in Prostate Cancer and Prostatic Diseases. Additionally, they found that the population faces disparities in access to care, with only approximately 60% receiving appropriate treatment.

    January 05, 2023
    Genetic Disorder Reference Sheet: HOXB13
    Genetics & genomics

    Genetic Disorder Reference Sheet: HOXB13

    An altered HOXB13 gene may increase a patient’s risk for developing prostate cancer. The HOXB13 gene is expressed in the prostate beginning in early development and affects prostate cell proliferation and differentiation and androgen receptor regulation. When it acts as a tumor suppressor gene, HOXB13 codes for a protein that regulates cell division. However, altered copies of HOXB13 are inactivated, meaning that it does not function properly or does not produce the protein it codes for, resulting in uncontrolled cell division.

    November 30, 2022
    Healthy Lifestyles Reduce Prostate Cancer Mortality in Patients With Genetic Risk
    Prostate cancer

    Healthy Lifestyles Reduce Prostate Cancer Mortality in Patients With Genetic Risk

    Patients with germline genetic variants that increase their risk of developing prostate cancer have a lower risk of developing lethal disease when following a healthy lifestyle, according to study findings that researchers reported in European Urology.

    November 23, 2022
    Caregiving for Metastatic Prostate Cancer Is Nearly a Full-Time Job
    Caregiver strain

    Caregiving for Metastatic Prostate Cancer Is Nearly a Full-Time Job

    Caregivers spend an average of 30 hours per week caring for patients with metastatic prostate cancer, researchers reported in study findings published in the Journal of Clinical Oncology.

    October 12, 2022
    FDA Approves Darolutamide Tablets for Metastatic Hormone-Sensitive Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Darolutamide Tablets for Metastatic Hormone-Sensitive Prostate Cancer

    On August 5, 2022, the U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa®) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer.

    August 08, 2022
    Use of Anxiety and Depression Drugs Linked to Increased PSA Testing
    Cancer research

    Use of Anxiety and Depression Drugs Linked to Increased PSA Testing

    Patients who take anxiety or depression medication are more likely to obtain prostate-specific antigen tests, according to study findings that researchers presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium.

    June 22, 2022
    FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

    On March 23, 2022, the U.S. Food and Drug Administration (FDA) approved lutetium lu 177 vipivotide tetraxetan (Pluvicto™) for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR)–pathway inhibition and taxane-based chemotherapy. 

    March 24, 2022
    How Liquid Biopsies Are Used in Cancer Treatment Selection
    Cancer treatments

    How Liquid Biopsies Are Used in Cancer Treatment Selection

    Biomarker testing is an essential tool when choosing the right treatment for many advanced solid cancers. However, tissue-based testing may take weeks to get results with a chance that not enough tissue was collected to complete the entire biomarker panel. Blood draw–based liquid biopsies may be a useful alternative to identify a tumor’s biomarker details and can be performed by testing for circulating tumor DNA (ctDNA).

    February 03, 2022
    New Radiopharmaceutical Improves Survival in Advanced Prostate Cancer
    Prostate cancer

    New Radiopharmaceutical Improves Survival in Advanced Prostate Cancer

    Among patients with metastatic, castration-resistant prostate cancer, treatment with the experimental 177Lu-PSMA-617 radiopharmaceutical, along with other standard treatments, improved survival by four months over treatment with standard therapies alone, researchers reported in the New England Journal of Medicine. The therapy targets the PMSA protein and may one day be an option when other treatments have failed.

    November 10, 2021
    ONS Bridge

    Nurses Are Key to Patients Navigating Genitourinary Cancers

    Nurses must serve as care coordinators for patients with genitourinary cancers because of the many tests, procedures, and self-care instructions they require, Clara Beaver, MSN, RN, AOCNS®, ACNS-BC®, and Joan Livingstone, BScN, RN, OCN®, both of Karmanos Cancer Institute at Wayne State University in Detroit, MI, said during a session at a ONS BridgeTM virtual conference on September 9, 2021. They emphasized the complexity of genitourinary cancers throughout diagnosis, treatment, and survivorship. Key nursing responsibilities include communicating with the care team, referring patients to other members of the interprofessional team, and advocating for patients’ needs.

    September 09, 2021
    Nursing Considerations for Prostate Cancer Survivorship Care
    Clinical practice

    Nursing Considerations for Prostate Cancer Survivorship Care

    Prostate cancer is the most common cancer among those assigned male at birth, with one in eight diagnosed during their lifetime. But with five-year survival rates of 90%, it’s also one of the most successful cancers to treat, making survivorship care even more important.

    June 03, 2021
    On May 27, 2021, the U.S. Food and Drug Administration (FDA) approved piflufolastat F 18 (Pylarify®), a drug for positron-emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in patients with prostate cancer.
    U.S. Food and Drug Administration (FDA)

    FDA Approves Second PSMA-Targeted PET Imaging Drug for Prostate Cancer

    On May 27, 2021, the U.S. Food and Drug Administration (FDA) approved piflufolastat F 18 (Pylarify®), a drug for positron-emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in patients with prostate cancer.

    June 01, 2021
    Genomics Test Guides Treatment Decisions for Prostate Cancer
    Genetics & genomics

    Genomics Test Guides Treatment Decisions for Prostate Cancer

    The Decipher genomics test, which measures activity of 22 genes among seven known cancer pathways, independently estimates patients’ risk of prostate cancer metastasis, death, and overall survival and helps identify patients most likely to benefit from hormone therapy, researchers reported in study findings published in JAMA Oncology.

    May 05, 2021
    Oncology Drug Reference Sheet: Relugolix
    Clinical practice

    Oncology Drug Reference Sheet: Relugolix

    On December 18, 2020, the U.S. Food and Drug Administration approved relugolix (OrgovyxTM) as the first oral hormone therapy for use in adult patients with advanced prostate cancer. 

    April 27, 2021
    Adding MRI to PSA Detects More Prostate Cancers Than PSA Alone
    Research

    Adding MRI to PSA Detects More Prostate Cancers Than PSA Alone

    Combining magnetic resonance imaging (MRI) with prostate-specific antigen (PSA) testing allows clinicians to detect twice as many clinically significant prostate cancers than PSA testing alone, according to study results published in JAMA Oncology.

    April 07, 2021
    FDA Approves Relugolix for Advanced Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Relugolix for Advanced Prostate Cancer

    On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved the first oral gonadotropin-releasing hormone receptor antagonist, relugolix, (Orgovyx™) for adult patients with advanced prostate cancer. 

    December 21, 2020
    CDC’s Virtual Simulation Guides Patients With Prostate Cancer From Screening to Treatment
    Prostate cancer

    CDC’s Virtual Simulation Guides Patients With Prostate Cancer From Screening to Treatment

    Nurses can now navigate patients with prostate cancer to a virtual simulation for guidance on all aspects of the disease, from screening to treatment. Plus, providers can interact with Nathan, the simulation avatar, in a clinical encounter to help improve their consultation skills when discussing screening and treatment decisions with men. The Centers for Disease Control and Prevention (CDC) released this resource after launching its popular simulation for patients with breast cancer.

    September 23, 2020
    FDA Approves Olaparib for HRR Gene-Mutated, Metastatic, Castration-Resistant Prostate Cancer
    Oncology drug research

    FDA Approves Olaparib for HRR Gene-Mutated, Metastatic, Castration-Resistant Prostate Cancer

    On May 19, 2020, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza®) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated, metastatic, castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.

    May 20, 2020
    FDA Grants Accelerated Approval to Rucaparib for BRCA-Mutated, Metastatic, Castration-Resistant Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Rucaparib for BRCA-Mutated, Metastatic, Castration-Resistant Prostate Cancer

    On May 15, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib (Rubraca®) for patients with deleterious BRCA mutation (germline or somatic)-associated, metastatic, castration-resistant prostate cancer (mCRPC) who had been treated with androgen receptor-directed therapy and taxane-based chemotherapy. 

    May 18, 2020
    Prostate Cancer Disparities Disappear With Equal Access to Care
    Cancer health disparities

    Prostate Cancer Disparities Disappear With Equal Access to Care

    Typically, African American men have worse outcomes from prostate cancer than their white counterparts. But according to the results of a new study in patients in the U.S. Department of Veterans Affairs (VA) health system where all patients have equal access to care, no disparities exist between the two groups—in fact, the African American men in the VA system had better outcomes than non-Hispanic whites. The findings were reported in Cancer.  

    March 27, 2020
    Adding MRI to Prostate Cancer Testing Improves Accuracy, NIH Study Says
    Prostate cancer

    Adding MRI to Prostate Cancer Testing Improves Accuracy, NIH Study Says

    Combining a traditional 12-point biopsy with magnetic resonance imaging (MRI) improves the accuracy of prostate cancer diagnosis, according to findings from a new National Institutes of Health (NIH) study published in the New England Journal of Medicine. 

    March 26, 2020
    Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations
    Prostate cancer

    Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations

    One in nine men will be diagnosed with prostate cancer, the second leading cause of death in men in the United States. Survival varies greatly depending on the disease’s severity and extent at diagnosis: five-year survival rates are near 100% for local or regional disease, but they drop to 30% for metastatic prostate cancer.

    January 27, 2020
    FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer

    On December 16, 2019, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi®) for patients with metastatic castration-sensitive prostate cancer.

    December 17, 2019
    FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

    On September 17, 2019, the U.S. Food and Drug Administration (FDA) approved apalutamide (ErleadaTM) for patients with metastatic castration-sensitive prostate cancer. Apalutamide was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer.

    September 18, 2019
    FDA Approves Darolutamide for Non-Metastatic Castration-Resistant Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Darolutamide for Nonmetastatic, Castration-Resistant Prostate Cancer

    On July 30, 2019, the U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa®) for non-metastatic castration-resistant prostate cancer.

    July 31, 2019
    Guidelines Insufficient for Prostate Cancer Germline Genetic Testing
    Research

    Guidelines Insufficient for Prostate Cancer Germline Genetic Testing

    According to researchers, only 43.8% of positive genetic variants detected in men with prostate cancer had corresponding recommendations for germline testing in National Comprehensive Cancer Network (NCCN) guidelines. The findings were published in JAMA Oncology.

    April 17, 2019
    Shorter EBRT for Early Prostate Cancer Has Similar Outcomes
    Prostate cancer

    Shorter EBRT for Early Prostate Cancer Has Similar Outcomes

    Patients receiving hypofractionated external-beam radiation therapy (EBRT) for early-stage prostate cancer experienced similar outcomes and toxicities as those receiving standard radiation at lower doses over a longer period of time, the American Society for Radiation Oncology, American Society of Clinical Oncology, and American Urological Association say in a new clinical guideline.

    February 20, 2019
    Lack of AR Expression May Cause Prostate Cancer Treatment Resistance
    Prostate cancer

    Lack of AR Expression May Cause Prostate Cancer Treatment Resistance

    Prostate cancer cells lacking androgen receptor (AR) expression do not respond to treatment and are more likely to grow, researchers reported in study findings published in Nature Communications. 

    December 24, 2018
    Neuroendocrine Prostate Cancer Subtype Is Aggressive and More Common Than Expected
    Research

    Neuroendocrine Prostate Cancer Subtype Is Aggressive and More Common Than Expected

    Nearly 20% of men with metastatic, castration-resistant prostate cancer had tumors that developed into the treatment-emergent small-cell neuroendocrine (t-SCNC) subtype, which is associated with shorter survival than other subtypes, according to findings from a study published in the Journal of Clinical Oncology.

    October 17, 2018
    NIH Launches Study Focused on Prostate Cancer Rates in African American Men
    Prostate cancer

    NIH Launches Study Focused on Prostate Cancer Rates in African American Men

    To better understand environmental and genetic impacts associated with prostate cancer in African American men, the National Institutes of Health (NIH) began a new study, Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress (RESPOND). The research program has received more than $26 million in funding and seeks to understand why African American men have disproportionally higher rates of aggressive prostate cancer than any other racial or ethnic population.

    September 12, 2018
    Annual Cancer Report Shows New Trends in Prostate Cancer
    Prostate cancer

    Annual Cancer Report Shows New Trends in Prostate Cancer

    After years of decline, the death rate trend for prostate cancer has stabilized from 2013–2015, according to the National Cancer Institute’s (NCI’s) 2018 Annual Report to the Nation on the Status of Cancer.

    August 01, 2018
    FDA Approves Enzalutamide for Castration-Resistant Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Enzalutamide for Castration-Resistant Prostate Cancer

    On July 13, 2018, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi), for patients with castration-resistant prostate cancer.

    July 17, 2018
    FDA Approves First Metastasis-Free Endpoint Treatment for Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves First Metastasis-Free Endpoint Treatment for Prostate Cancer

    Breakthroughs and new treatments are moving faster than ever. Getting treatments approved by the U.S. Food and Drug Administration (FDA) is crucial whenever new options are making way to patients with cancer. In February 2018, the FDA approved apalutamide for the treatment of nonmetastatic prostate cancer that continues to grow despite treatment with hormone therapy, the first FDA-approved treatment for nonmetastatic, castration-resistant prostate cancer.

    March 08, 2018
    fda
    U.S. Food and Drug Administration (FDA)

    FDA Approves Abiraterone Acetate With Prednisone for High-Risk Metastatic CSPC

    On February 7, 2018, the U.S. Food and Drug Administration (FDA) approved abiraterone acetate tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC).

    February 08, 2018
    Height and Weight May Be Linked to Aggressive Prostate Cancer
    Prostate cancer

    Height and Weight May Be Linked to Aggressive Prostate Cancer

    Taller men and those with a higher body mass index (BMI) may be at increased risk for high-grade prostate cancer and disease-related mortality, according to the results of a study published in BMC Medicine.

    November 02, 2017
    Targeted Treatment for Prostate Cancer
    Prostate cancer

    New Blood Test Paves Way for Targeted Treatment for Prostate Cancer

    A new three-in-one blood test that analyzes cancer DNA in the bloodstream before and during treatment will allow providers to understand and track which patients are likely to benefit from treatment with olaparib, a PARP inhibitor. Additionally, researchers found which genetic mutations prostate cancers use to resist treatment with olaparib. The study was published in Cancer Discovery.

    September 13, 2017
    improving oncology care through patient reported outcomes
    Patient reported outcomes (PROs)

    Improving Cancer Care Through Patient-Reported Outcomes

    Technology can—at times—seem miraculous, especially as it evolves in healthcare settings. Simple technologic tools have been able to lower costs, increase efficiency, minimize delays in treatment times, and even provide new, lifesaving procedures for cancer treatment.

    August 01, 2017
    Prostate Cancer Risk
    Cancer research

    Less Sleep May Increase Risk of Death From Prostate Cancer

    Men younger than 65 years who sleep less than six hours per night have an increased risk of death from prostate cancer, according to the results of a study presented at the American Association for Cancer Research 2017 annual meeting.

    June 28, 2017
    Prostate Screening
    Prostate cancer

    Revised USPSTF Draft Guidelines Recommend Individual Prostate Cancer Screening Decisions

    The U.S. Preventive Services Task Force (USPSTF) has issued new draft revisions for prostate cancer screening guidelines. In the draft, the USPSTF has changed its previous stance on prostate-specific antigen (PSA) screening tests for men aged 55–69. The drafted guidelines now recommend PSA screening tests for men aged 55–69 based on individual assessment. The USPSTF has upgraded its recommendation from D to C, encouraging physicians to discuss with their patients whether PSA testing is right for them. The USPSTF still recommends against PSA screening tests in patients aged 70 or older.

    April 13, 2017
    Cancer screening

    Metastatic Prostate Cancer Increasing in United States

    The number of new U.S. cases of metastatic prostate cancer increased by 72% from 2004–2013, according to a new study published in Prostate Cancer and Prostatic Diseases.
    September 06, 2016
    Oncology drug research

    New Class of Drugs Shows Promise in Treatment-Resistant Prostate Cancer

    Researchers in the United Kingdom are looking at a new class of drugs that attacks cancer indirectly through a network of signals, which may prevent or overcome drug resistance. The findings of the study were published in Cancer Research.
    July 26, 2016
    Prostate cancer

    Prostate Radiotherapy May Increase Bladder Cancer Risk

    Patients with prostate cancer who undergo radiation treatment, especially brachytherapy, may be at increased risk of bladder cancer more than 10 years later, according to the results of a new study presented at the American Urological Association annual meeting.
    July 12, 2016
    Oncology drug research

    FDA Approves Enzalutamide for Patients With Prostate Cancer Who Have not Received Prior Chemotherapy

    On September 10, 2014, the U.S. Food and Drug Administration approved enzalutamide for the treatment of patients with metastatic castration-resistant prostate cancer.
    September 11, 2014
    Prostate cancer

    Prostate Cancer Nursing Management Is Critical to Quality Care

    Prostate cancer nursing management must be well understood because prostate cancer is the second most common cancer in men after skin cancer; however, prostate cancer can be successfully treated. According to the American Cancer Society, more than two million men in the United States are prostate cancer survivors.
    September 18, 2013
    Clinical practice

    FDA Approves Xofigo for Castration-Resistant Prostate Cancer

    On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Xofigo Injection, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.
    May 21, 2013
    Cancer screening

    Controversial Cancer Screening Guidelines Can Help Nurses Start the Screening Conversation

    The con­tro­versy over prostate can­cer screen­ing guide­lines heated up last Novem­ber
    August 01, 2012
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲